Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2005-07-18
2010-06-22
Schwadron, Ron (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S144100, C424S153100, C424S155100, C424S156100, C424S173100, C424S174100, C424S143100, C435S069600, C435S320100, C435S325000, C435S326000, C435S328000, C435S343100, C435S344000, C435S344100, C435S358000, C530S387300, C530S388220, C530S388730, C530S333000, C530S388850, C536S023530
Reexamination Certificate
active
07740847
ABSTRACT:
The present invention provides humanized anti-CD20 antibodies comprising a human IgG1 Fc region comprising an isoleucine at position 247 and a glutamine at position 339 as well as nucleic acids encoding the antibodies and methods of using the antibodies for treating lymphoma. Furthermore, the invention provides compositions comprising the antibodies and methods of producing them.
REFERENCES:
patent: 4861579 (1989-08-01), Meyer et al.
patent: 5348876 (1994-09-01), Michaelsen et al.
patent: 5354847 (1994-10-01), Liu et al.
patent: 5545404 (1996-08-01), Page
patent: 5545405 (1996-08-01), Page
patent: 5550362 (1996-08-01), Sherman
patent: 5595721 (1997-01-01), Kaminski et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5677180 (1997-10-01), Robinson et al.
patent: 5721108 (1998-02-01), Robinson et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5776456 (1998-07-01), Anderson et al.
patent: 5843398 (1998-12-01), Kaminski et al.
patent: 5843439 (1998-12-01), Anderson et al.
patent: 5985599 (1999-11-01), McKenzie et al.
patent: 6015542 (2000-01-01), Kaminski et al.
patent: 6090365 (2000-07-01), Kaminski et al.
patent: 6120767 (2000-09-01), Robinson et al.
patent: 6121022 (2000-09-01), Presta et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6171586 (2001-01-01), Lam et al.
patent: 6183744 (2001-02-01), Goldenberg
patent: 6187287 (2001-02-01), Leung et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 6204023 (2001-03-01), Robinson et al.
patent: 6224866 (2001-05-01), Barbera-Guillem
patent: 6242195 (2001-06-01), Idusogie et al.
patent: 6277375 (2001-08-01), Ward
patent: 6287537 (2001-09-01), Kaminski et al.
patent: 6306393 (2001-10-01), Goldenberg
patent: 6399061 (2002-06-01), Anderson et al.
patent: 6455043 (2002-09-01), Grillo-Lopez
patent: 6528624 (2003-03-01), Idusogie et al.
patent: 6538124 (2003-03-01), Idusogie et al.
patent: 6565827 (2003-05-01), Kaminski et al.
patent: 6652852 (2003-11-01), Robinson et al.
patent: 6682734 (2004-01-01), Anderson et al.
patent: 6737056 (2004-05-01), Presta
patent: 6821505 (2004-11-01), Ward
patent: 6893625 (2005-05-01), Robinson et al.
patent: 7083784 (2006-08-01), Dall'Acqua et al.
patent: 2002/0164326 (2002-11-01), Young et al.
patent: 2002/0197256 (2002-12-01), Grewal
patent: 2003/0219433 (2003-11-01), Hansen et al.
patent: 2004/0002587 (2004-01-01), Watkins et al.
patent: 2004/0185045 (2004-09-01), Koenig et al.
patent: 2005/0054832 (2005-03-01), Lazar et al.
patent: 2005/0202023 (2005-09-01), Ledbetter et al.
patent: 2006/0024300 (2006-02-01), Adams et al.
patent: 2006/0034836 (2006-02-01), Gillies et al.
patent: 2006/0246004 (2006-11-01), Adams et al.
patent: 2006/0251652 (2006-11-01), Watkins et al.
patent: WO 88/04936 (1988-07-01), None
patent: WO 88/07089 (1988-09-01), None
patent: WO 92/07466 (1992-05-01), None
patent: WO 92/16562 (1992-10-01), None
patent: WO 94/11026 (1994-05-01), None
patent: WO 94/29351 (1994-12-01), None
patent: WO 95/03770 (1995-02-01), None
patent: WO 95/05468 (1995-02-01), None
patent: WO 97/28267 (1997-08-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 97/44362 (1997-11-01), None
patent: WO 98/05787 (1998-02-01), None
patent: WO 98/23289 (1998-06-01), None
patent: WO 98/52975 (1998-11-01), None
patent: WO 98/56418 (1998-12-01), None
patent: WO 98/58964 (1998-12-01), None
patent: WO 99/22764 (1999-05-01), None
patent: WO 99/51642 (1999-10-01), None
patent: WO 99/58572 (1999-11-01), None
patent: WO 00/09160 (2000-02-01), None
patent: WO 00/09560 (2000-02-01), None
patent: WO 00/20864 (2000-04-01), None
patent: WO 00/27428 (2000-05-01), None
patent: WO 00/27433 (2000-05-01), None
patent: WO 00/29584 (2000-05-01), None
patent: WO 00/42072 (2000-07-01), None
patent: WO 00/44788 (2000-08-01), None
patent: WO 00/67795 (2000-11-01), None
patent: WO 00/67796 (2000-11-01), None
patent: WO 00/74718 (2000-12-01), None
patent: WO 00/76542 (2000-12-01), None
patent: WO 01/03734 (2001-01-01), None
patent: WO 01/10460 (2001-02-01), None
patent: WO 01/10462 (2001-02-01), None
patent: WO 01/13945 (2001-03-01), None
patent: WO 01/74388 (2001-10-01), None
patent: WO 01/79299 (2001-10-01), None
patent: WO 01/80884 (2001-11-01), None
patent: WO 01/97858 (2001-12-01), None
patent: WO 02/34790 (2002-05-01), None
patent: WO 02/060919 (2002-08-01), None
patent: WO 02/060955 (2002-08-01), None
patent: WO 02/079255 (2002-10-01), None
patent: WO 03/002607 (2003-01-01), None
patent: WO 03/061694 (2003-07-01), None
patent: WO 03/068821 (2003-08-01), None
patent: WO 03/074679 (2003-09-01), None
patent: WO 2004/029207 (2004-04-01), None
patent: WO 2004/035607 (2004-04-01), None
patent: WO 2004/056312 (2004-07-01), None
patent: WO 2004/063351 (2004-07-01), None
patent: WO 2004/074455 (2004-09-01), None
patent: WO 2004/ 091657 (2004-10-01), None
patent: WO 2004/ 099249 (2004-11-01), None
patent: WO 2004/103404 (2004-12-01), None
patent: WO 2005/000901 (2005-01-01), None
patent: WO 2005/016969 (2005-02-01), None
patent: WO 2005/044859 (2005-05-01), None
patent: WO 2005/056606 (2005-06-01), None
patent: WO 2005/070963 (2005-08-01), None
patent: WO 2005/103081 (2005-11-01), None
patent: WO 2006/019447 (2006-02-01), None
patent: WO 2006/020114 (2006-02-01), None
patent: WO 2006/042240 (2006-04-01), None
patent: WO 2006/053301 (2006-05-01), None
patent: WO 2006/064121 (2006-06-01), None
patent: WO 2006/076651 (2006-07-01), None
patent: WO 2006/084264 (2006-08-01), None
patent: WO 2006/085967 (2006-08-01), None
patent: WO 2006/105338 (2006-10-01), None
Carter et al., “Humanization of an anti-p185HER2 Antibody for Human Cancer Therapy,” Proc. Natl. Acad. Sci. USA, vol. 89, No. 10, pp. 4285-4289 (May 1992).
Clynes et al., “Inhibitory Fc Receptors Modulate In Vivo Cytoxicity Against Tumor Targets,” Nature Med., vol. 6, No. 4, pp. 443-446 (Apr. 2000).
Eisenberg, R, et al., “The therapeutic potential of anti-CD20 What do B-cells do?,” Clinical Immunology, vol. 117, pp. 207-213, 2005.
Glennie, MJ, et al., “Renaissance of cancer therapeutic antibodies,” Drug Discovery Today, vol. 8, No. 11, pp. 503-510, (Jun. 1, 2003).
Gopal, AK, et al., “Clinical applications of anti-CD20 antibodies,” Journal of Laboratory and Clinical Medicine, vol. 134, No. 5, pp. 445-450, 1999.
Grossbard, ML, et al., “Monoclonal Antibody-Based Therapies of Leukemia and Lymphoma,” Blood, vol. 80, No. 4, pp. 863-878 (Aug. 15, 1992).
Hong, K, et al , “Simple quantitative live cell and anti-idiotypic based ELISA for humanized antibody directed to cell surface protein CD20,” Journal of Immunological Methods vol. 294, pp. 189-197 (2004).
Idusogie, EE, et al., “Mapping of the Clq Binding Site on Rituxan, A Chimeric Antibody with a Human IgGl Fc,” Journal of Immunology, vol. 164, No. 8, pp, 4178-4184 (2000).
Idusogie, EE, et al., “Engineered Antibodies with Increased Activity to Recruit Complement,” Journal of Immunology, vol. 166, No. 4, pp, 2571-2575 (Feb. 15, 2001).
Jones, PT, et al., “Replacing the Complementarity-Determining Regions in a Human Antibody with Those From a Mouse” Nature 321:522-525 (May 29, 1986).
Liu, AY, et al., “Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity,” Journal of Immunology, vol. 139, No. 10, pp. 3521-3526 (1987).
Longo, DL, “Immunotherapy for non-Hodgkin's lymphoma”, Current Opinion in Oncology, vol. 8, pp. 353-359, 1996.
Maloney, DG, et al., “Newer Treatments for Non-Hoggkin's Lymphoma: Monoclonal Antibodies”, Oncology, vol. 12, No. 10, Supplement No. 8, pp, 63-76, (Oct. 1998).
Martin, F, et al., “Pathogenic roles of B cells in Human Autoimmunity; Insights from the Clinic,” Immunity, vol. 20, No. 5, pp. 517-527 (May 2004).
Nadler, LM, et al., “A Unique Cell Surface Antigen Identifying Lymphoid Malignancies of B Cell Origin,” J. Clin. Invest, vol. 67, pp. 134-140, (Jan. 1981).
Paul, WE, “Fv Structure
Allan Barrett
Jiang Weidong
Tang Ying
Watkins Jeffry Dean
Applied Molecular Evolution, Inc.
Schwadron Ron
Sharp Robert L.
Wiskerchen MaryAnn
LandOfFree
Variant Fc regions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Variant Fc regions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Variant Fc regions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4155268